AZN.L Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 20:09):

Stats
Tagesvolumen	1.64M
Durchschnittsvolumen	2.94M
Marktkapitalisierung	186.80B
EPS	£0 ( 2024-04-24 )
Nächstes Ertragsdatum	( £1.530 ) 2024-05-31
Last Dividend	£71.80 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	37.19
ATR14	£7.95 (0.07%)

Volumen Korrelation

Lang: 0.07 (neutral)

Kurz: -0.06 (neutral)

Signal:(65.972) Neutral

AstraZeneca PLC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

AstraZeneca PLC Korrelation - Währung/Rohstoff

-0.70
( moderate negative )

-0.65
( weak negative )

-0.84
( strong negative )

-0.70
( moderate negative )

0.84
( strong )

AstraZeneca PLC Finanzdaten

Annual	2023
Umsatz:	£45.81B
Bruttogewinn:	£37.54B (81.95 %)
EPS:	£3.84

FY	2023
Umsatz:	£45.81B
Bruttogewinn:	£37.54B (81.95 %)
EPS:	£3.84

FY	2022
Umsatz:	£44.35B
Bruttogewinn:	£31.96B (72.06 %)
EPS:	£2.12

FY	2021
Umsatz:	£37.42B
Bruttogewinn:	£24.98B (66.76 %)
EPS:	£0.0854

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£76.40 (N/A)	£0 (N/A)	£162.80 (N/A)	£0 (N/A)	£71.80 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

AstraZeneca PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.82 - Stable (3.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£10.50	1993-09-20
Last Dividend	£71.80	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	61	--
Total Paid Out	£3 651.80	--
Avg. Dividend % Per Year	1.07%	--
Score	4.42	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.82
Div. Directional Score	7.92	--

Next Divdend (Est)
(2024-07-01)

£70.63 Estimate 7.48 %

Dividend Stability

0.30 Very Poor

Dividend Score

4.42

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	£10.50	1.75%
1994	£27.75	3.38%
1995	£29.00	3.38%
1996	£32.25	2.65%
1997	£36.00	2.24%
1998	£39.00	1.87%
1999	£42.20	1.65%
2000	£44.39	1.77%
2001	£47.56	1.41%
2002	£47.90	1.55%
2003	£43.95	1.98%
2004	£45.40	1.69%
2005	£56.20	2.98%
2006	£78.40	2.73%
2007	£88.30	3.18%
2008	£95.50	4.45%
2009	£140.80	5.04%
2010	£150.30	5.11%
2011	£168.60	5.64%
2012	£181.70	5.96%
2013	£179.70	6.05%
2014	£169.90	4.78%
2015	£182.50	3.98%
2016	£199.70	4.46%
2017	£219.10	4.94%
2018	£202.00	3.96%
2019	£218.70	3.70%
2020	£216.00	2.82%
2021	£202.20	2.72%
2022	£221.70	2.62%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHED.L	Dividend Knight	2023-06-29	Semi-Annually	9	2.67%
IEM.L	Dividend Knight	2023-08-10	Annually	18	0.53%
BKG.L	Dividend Knight	2023-08-17	Annually	32	1.27%
ZTF.L	Dividend Knight	2023-09-07	Annually	30	1.13%
NWOR.L	Dividend Knight	2023-06-01	Insufficient data to determine frequency	2	0.88%
ENOG.L	Dividend King	2023-09-14	Quarterly	3	3.46%
SSE.L	Dividend King	2023-07-27	Semi-Annually	32	3.65%
JEMI.L	Dividend King	2023-09-14	Quarterly	14	2.32%
BWY.L	Dividend Knight	2023-05-25	Annually	33	2.07%
PRSR.L	Dividend Knight	2023-08-10	Quarterly	7	2.62%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.133	1.500	7.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0619	1.200	7.94	9.52	[0 - 0.3]
returnOnEquityTTM	0.168	1.500	9.25	10.00	[0.1 - 1]
payoutRatioTTM	0.706	-1.000	2.94	-2.94	[0 - 1]
currentRatioTTM	0.886	0.800	-0.572	-0.458	[1 - 3]
quickRatioTTM	0.661	0.800	-0.820	-0.656	[0.8 - 2.5]
cashRatioTTM	0.271	1.500	9.60	10.00	[0.2 - 2]
debtRatioTTM	0.338	-1.500	4.37	-6.56	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.73	2.00	8.13	10.00	[0 - 20]
debtEquityRatioTTM	0.923	-1.500	6.31	-9.46	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.465	0.800	-0.230	-0.184	[0.5 - 2]
Total Score				11.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.99	1.000	6.36	0	[1 - 100]
returnOnEquityTTM	0.168	2.50	9.52	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.73	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	1.189	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
payoutRatioTTM	0.706	1.500	2.94	-2.94	[0 - 1]
pegRatioTTM	-56.74	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.204	1.000	7.41	0	[0.1 - 0.5]
Total Score				4.82

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.